A randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
Twenty-nine HBV carriers were randomised to receive ARA-AMP 10 mg/kg/day given as intramuscular injections 12 h apart for 5 days followed by 5 mg/kg/day for 23 days (15 patients) or no treatment (14 patients). Serum HBV-DNA polymerase and DNA decreased in all patients during therapy and 6 patients lost HBeAg. Five developed anti-HBe and 1 lost HBsAg and developed anti-HBs. No such changes occurred in the untreated control group over the 18-month period of observation. A 1-month course of ARA-AMP inhibits productive HBV replication and in some patients this is associated with a later loss of HBeAg and development of anti-HBe. However, intercurrent infection occurred in 3 of the treated patients with other hepatotrophic viruses known to inhibit HBV replication.
D000328:Adult; D001088:Arabinonucleotides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000097:blood; D004259:DNA-Directed DNA Polymerase / Q000097:blood; D006509:Hepatitis B / Q000188:drug therapy*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics / Q000502:physiology; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006716:Homosexuality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D001084:Vidarabine Phosphate / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D001088:Arabinonucleotides; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D001084:Vidarabine Phosphate; D004259:DNA-Directed DNA Polymerase